Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Revenue (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Revenue for 2 consecutive years, with $53.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 83.92% to $53.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $158.2 million, a 20.6% increase, with the full-year FY2025 number at $158.2 million, up 20.6% from a year prior.
  • Revenue was $53.7 million for Q4 2025 at Day One Biopharmaceuticals, up from $39.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $93.8 million in Q3 2024 to a low of $8.2 million in Q2 2024.